Alpa Laboratories Ltd

Alpa Laboratorie Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alpa Laboratories Ltd

₹ 93.4 2.13%
26 Jul - close price
alpalabs.in BSE: 532878 NSE: ALPA
About

Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]

Key Points

Business Overview:[1]
ALL is a WHO-GMP and ISO 9001:2000 certified company. It manufactures a wide range of Pharmaceutical Finished Dosage Forms under its own brand and for other Indian and multinational companies. The product range includes a wide variety of ethical, generic, and over-the-counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use

Website BSE NSE
  • Market Cap ₹ 197 Cr.
  • Current Price ₹ 93.4
  • High / Low ₹ 115 / 68.3
  • Stock P/E 11.7
  • Book Value ₹ 72.2
  • Dividend Yield 0.00 %
  • ROCE 14.3 %
  • ROE 11.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 80.7% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 7.16% over past five years.
  • Company has a low return on equity of 8.92% over last 3 years.
  • Earnings include an other income of Rs.14.9 Cr.
  • Working capital days have increased from 246 days to 458 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
24.99 31.52 26.26 29.33 25.16 22.42 13.54 27.31 29.16 25.43 32.39 27.31 23.61
23.77 28.99 22.73 25.61 24.27 20.96 19.23 24.69 19.94 26.57 29.04 24.88 20.10
Operating Profit 1.22 2.53 3.53 3.72 0.89 1.46 -5.69 2.62 9.22 -1.14 3.35 2.43 3.51
OPM % 4.88% 8.03% 13.44% 12.68% 3.54% 6.51% -42.02% 9.59% 31.62% -4.48% 10.34% 8.90% 14.87%
0.66 4.27 2.67 2.20 1.64 1.61 6.33 2.67 -0.69 4.47 2.95 3.55 3.98
Interest 0.01 0.04 0.06 0.08 0.05 0.03 0.08 0.07 0.04 0.02 0.02 0.02 0.29
Depreciation 0.35 0.31 0.42 0.43 0.50 0.34 0.36 0.10 0.53 0.28 0.49 0.66 0.52
Profit before tax 1.52 6.45 5.72 5.41 1.98 2.70 0.20 5.12 7.96 3.03 5.79 5.30 6.68
Tax % 232.89% 0.00% 0.00% 0.00% 276.26% 0.00% 0.00% 0.00% 41.58% 0.00% 0.00% 14.91% 46.71%
-2.02 6.46 5.72 5.41 -3.49 2.70 0.20 5.12 4.65 3.03 5.79 4.51 3.55
EPS in Rs -0.96 3.07 2.72 2.57 -1.66 1.28 0.10 2.43 2.21 1.44 2.75 2.14 1.69
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
56 57 53 63 62 77 85 97 112 93 109
51 54 47 56 58 76 80 90 101 85 101
Operating Profit 6 3 7 7 4 1 6 8 11 8 8
OPM % 10% 6% 13% 11% 7% 1% 7% 8% 10% 9% 7%
1 2 5 3 5 5 0 4 11 9 15
Interest 2 2 1 2 1 1 0 0 0 0 0
Depreciation 9 6 1 3 3 3 3 1 2 1 2
Profit before tax -5 -3 10 6 5 3 3 11 20 16 21
Tax % 4% -48% 30% 55% 39% 63% 36% 33% 28% 21% 19%
-5 -1 7 3 3 1 2 7 14 13 17
EPS in Rs -2.45 -0.67 3.26 1.20 1.34 0.48 0.88 3.45 6.70 5.98 7.98
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 7%
5 Years: 7%
3 Years: 4%
TTM: 17%
Compounded Profit Growth
10 Years: 18%
5 Years: 81%
3 Years: 48%
TTM: 69%
Stock Price CAGR
10 Years: 23%
5 Years: 41%
3 Years: 24%
1 Year: 34%
Return on Equity
10 Years: 5%
5 Years: 7%
3 Years: 9%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 21 21 21 21 21 21 21 21 21 21 21
Reserves 67 66 72 74 77 77 79 87 101 114 131
23 29 24 11 6 2 0 0 6 2 5
15 13 27 20 18 21 21 33 28 30 25
Total Liabilities 127 128 144 126 122 121 121 140 155 167 183
73 5 15 15 10 8 6 7 9 7 11
CWIP 0 0 0 0 0 0 1 2 0 0 0
Investments 0 10 12 13 31 49 57 51 75 78 98
54 113 118 97 81 65 58 81 71 82 73
Total Assets 127 128 144 126 122 121 121 140 155 167 183

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
8 -2 -22 17 -13 -1 18 -2 10 9 4
-2 37 -8 -2 -11 -15 -11 6 -16 2 -13
4 7 -6 -15 9 -5 -1 0 5 -4 3
Net Cash Flow 10 42 -36 0 -15 -20 5 4 -0 7 -7

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 130 156 234 168 153 142 105 133 124 184 139
Inventory Days 148 76 196 131 138 105 90 102 81 84 73
Days Payable 121 91 244 140 134 99 98 152 78 100 63
Cash Conversion Cycle 157 141 187 159 157 149 97 83 127 168 149
Working Capital Days 169 177 369 233 238 199 125 141 131 149 458
ROCE % 0% 10% 8% 6% 3% 5% 7% 9% 10% 14%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
56.66% 56.66% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29%
0.00% 0.09% 0.56% 0.21% 0.14% 0.00% 0.00% 0.00% 0.11% 0.95% 0.50% 0.36%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
0.00% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
43.34% 43.20% 42.15% 42.50% 42.56% 42.70% 42.70% 42.70% 42.59% 41.74% 42.21% 42.35%
No. of Shareholders 15,59516,11418,77518,79618,84019,09419,13718,74518,56518,68218,69018,116

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings